Month: September 2023

Specific coding expected to improve disease awareness, understanding and diagnosis and may enhance access to therapies for patients with BBS BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for Bardet-Biedl Syndrome (BBS) was approved by the Centers for Disease Control and Prevention (CDC). The new code, Q87.83 Bardet-Biedl syndrome (BBS), takes effect Oct. 1, 2023. “Finding and connecting patients, families and physicians across the country has been extremely challenging...

TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD) (TSX:ABX)  (“Barrick”) announced today that following the August 24, 2023 closing of a private placement of units (the “Private Placement”) by Cascadia Minerals Ltd. (“Cascadia”), Barrick’s 2,788,696 common shares of Cascadia represent approximately 7.6% of Cascadia’s outstanding common shares. Barrick did not acquire any securities in the Private Placement and, as a result of the Private Placement, Barrick has ceased to be an insider of Cascadia pursuant to Canadian securities laws. Barrick is holding its Cascadia common shares for investment purposes. Depending on market conditions and other factors, including Cascadia’s business and financial condition, Barrick may acquire additional common shares or other securities of Cascadia or dispose of some...

MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) — Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Health (the “Acquisition”) by the Issuer and certain of its affiliated entities (such affiliates, together with the Issuer, the “Purchasing Entities”) and related refinancings. The Purchasing Entities were newly-formed entities established by a consortium of private investment funds led by Elliott Investment Management L.P. and its affiliates, Patient Square...

Figure 1Childress – Phase 1 (100MW) construction progressFigure 2Childress – second data center building foundationDaily average operating hashrate chartDaily average operating hashrate chartNegative 8c Power at Childress in August Targeting Next-Gen Compute and Generative AI with NVIDIA H100 GPUs SYDNEY, Australia, Sept. 06, 2023 (GLOBE NEWSWIRE) — Iris Energy Limited (NASDAQ: IREN) (“Iris Energy” or “the Company”), a leading owner and operator of institutional-grade, highly efficient proprietary Bitcoin mining data centers powered by 100% renewable energy, today published a monthly investor update for August 2023, containing its results from operations as well as business updates. Key Highlights1Key metrics2 Aug-23Average operating hashrate (PH/s) 5,493Bitcoin mined 410Mining...

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) — Rapid7, Inc. (“Rapid7”) (Nasdaq: RPD) today announced the pricing of $260.0 million aggregate principal amount of 1.25% convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $250.0 million. Rapid7 also granted the initial purchasers of the notes an option to purchase up to an additional $40.0 million aggregate principal amount of notes. The sale of the notes is expected to close on September 8, 2023, subject to customary closing conditions. The notes will be general unsecured obligations of Rapid7 and will accrue...

Murphy Brings Hypergrowth Startup and Big Four Accounting Firm Experience as Nxu Focuses on Internal Efficiencies MESA, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) — Nxu Inc., (NASDAQ: NXU) (“Nxu”, “the Company”), a domestic technology company creating EV charging and energy storage solutions for the infrastructure we need to power our electrified future, is pleased to welcome Jessica Murphy, who joins the Company as Controller. Murphy’s deep experience in financial reporting and public company accounting in both rapid-growth startup settings and newly public company settings will bring valuable expertise in financial controls and operational expenditures. “Adding Jessica’s expertise to the team is a key part of our strategy to enhance the Company’s financial processes and reduce dependencies on external resources,” said Nxu Chief Financial...

LONGUEUIL, Quebec, Sept. 06, 2023 (GLOBE NEWSWIRE) — Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to report that a spodumene-bearing pegmatite boulder field containing at least 12 mineralized boulders has been identified on the Galinée Property (the “Property”) in the Eeyou Istchee James Bay region of Quebec. These encouraging preliminary field results obtained by Azimut and its partner SOQUEM Inc. (“SOQUEM”) confirm the strong prospectivity of the Property and support the upcoming maiden drilling program targeting the area immediately south of the Adina lithium discovery (Winsome Resources). The minimum 1,600-metre core drilling program will be initiated shortly. In addition to Galinée, substantial concurrent exploration programs are already underway or will soon commence following...

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, taking place in Bonn, Germany, from September 14-16, 2023. Presentation details:Title: Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trialPresenter: Emel Aygören-Pürsün, M.D.Date, Time: Friday, September 15, 5:15-6:30 p.m. CESTPoster ID: A-194Title: Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release...

ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, will attend the Morgan Stanley 21st Annual Global Healthcare Conference, taking place in New York from September 11-13, 2023. Morgan Conn, Ph.D., Chief Business Officer of Pharvaris, will participate in a fireside chat on Monday, September 11, at 3:35 p.m. ET. A live audio webcast of the Morgan Stanley 21st Annual Global Healthcare Conference fireside chat will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation. About PharvarisBuilding on its deep-seated...